More on TBPH
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $13.58 |
|
|||
| Open | $13.28 | ||||
| 52 Wk High | $38.92 | ||||
| 52 Wk Low | $12.87 | ||||
| Day High | $13.75 | ||||
| Day Low | $13.28 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,178,216 | ||||
- Oppenheimer Downgrades Theravance Biopharma (TBPH) to Perform
- B.Riley Downgrades Theravance Biopharma (TBPH) to Neutral
- Theravance Biopharma (TBPH) PT Lowered to $21 at BTIG following trial miss
- Form 8-K Theravance Biopharma, For: Mar 03
- Theravance Biopharma drug trial fails, company cuts costs 60%
- Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
- Theravance Biopharma (TBPH) Halted, News Pending
- Theravance Biopharma (TBPH) PT Raised to $27 at H.C. Wainwright
- Form 4 Theravance Biopharma, For: Feb 20 Filed by: Winningham Rick E
- Form 4 Theravance Biopharma, For: Feb 20 Filed by: Sawaf Aziz
Entities mentioned with TBPH
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Baupost Group | View Related Stories »
- Seth Klarman | View Related Stories »
- Needham & Company | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
